1. Home
  2. UTHR vs SYF Comparison

UTHR vs SYF Comparison

Compare UTHR & SYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • SYF
  • Stock Information
  • Founded
  • UTHR 1996
  • SYF 1932
  • Country
  • UTHR United States
  • SYF United States
  • Employees
  • UTHR N/A
  • SYF N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • SYF Finance: Consumer Services
  • Sector
  • UTHR Health Care
  • SYF Finance
  • Exchange
  • UTHR Nasdaq
  • SYF Nasdaq
  • Market Cap
  • UTHR 16.2B
  • SYF 19.4B
  • IPO Year
  • UTHR 1999
  • SYF N/A
  • Fundamental
  • Price
  • UTHR $359.23
  • SYF $65.53
  • Analyst Decision
  • UTHR Buy
  • SYF Buy
  • Analyst Count
  • UTHR 14
  • SYF 22
  • Target Price
  • UTHR $370.86
  • SYF $59.33
  • AVG Volume (30 Days)
  • UTHR 313.6K
  • SYF 3.8M
  • Earning Date
  • UTHR 02-19-2025
  • SYF 01-21-2025
  • Dividend Yield
  • UTHR N/A
  • SYF 1.53%
  • EPS Growth
  • UTHR 25.10
  • SYF 41.97
  • EPS
  • UTHR 22.72
  • SYF 7.67
  • Revenue
  • UTHR $2,756,200,000.00
  • SYF $9,007,000,000.00
  • Revenue This Year
  • UTHR $26.32
  • SYF N/A
  • Revenue Next Year
  • UTHR $10.37
  • SYF $1.63
  • P/E Ratio
  • UTHR $15.82
  • SYF $8.54
  • Revenue Growth
  • UTHR 25.04
  • SYF 16.99
  • 52 Week Low
  • UTHR $208.62
  • SYF $35.29
  • 52 Week High
  • UTHR $417.82
  • SYF $69.39
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 43.90
  • SYF 47.26
  • Support Level
  • UTHR $358.82
  • SYF $63.22
  • Resistance Level
  • UTHR $383.00
  • SYF $68.98
  • Average True Range (ATR)
  • UTHR 9.97
  • SYF 1.83
  • MACD
  • UTHR -0.80
  • SYF -0.79
  • Stochastic Oscillator
  • UTHR 29.51
  • SYF 23.19

About UTHR United Therapeutics Corporation

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

About SYF Synchrony Financial

Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).

Share on Social Networks: